A little debt'll do 'ya

ZS Pharma Inc. (NASDAQ:ZSPH) wasted no time topping off its $123 million IPO with a $20 million debt facility through MidCap Financial to support development of hyperkalemia compound ZS-9, which has Phase III data coming in 4Q.